Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals (EYPT – Research Report), Qiagen (QGEN – Research Report) and Neurosense Therapeutics Ltd. (NRSN – Research Report).
EyePoint Pharmaceuticals (EYPT)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on EyePoint Pharmaceuticals today and set a price target of $25.00. The company’s shares closed last Thursday at $7.35.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on EyePoint Pharmaceuticals is a Strong Buy with an average price target of $29.67, a 280.9% upside from current levels. In a report issued on April 20, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $33.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Qiagen (QGEN)
Jefferies analyst Peter Welford maintained a Hold rating on Qiagen today and set a price target of EUR42.00. The company’s shares closed last Thursday at $46.45.
According to TipRanks.com, Welford is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Qiagen with a $58.10 average price target, which is a 25.1% upside from current levels. In a report released today, UBS also maintained a Hold rating on the stock.
Neurosense Therapeutics Ltd. (NRSN)
Maxim Group analyst Naz Rahman maintained a Buy rating on Neurosense Therapeutics Ltd. yesterday and set a price target of $7.00. The company’s shares closed last Thursday at $1.67.
According to TipRanks.com, Rahman is a 3-star analyst with an average return of
Neurosense Therapeutics Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EYPT:
- EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
- EyePoint expects cash to fund operations into 2H of 2024
- EyePoint reports Q1 EPS (56c), consensus (68c)
- EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023
- Biotech Alert: Searches spiking for these stocks today
